EUCTR2009-015988-13-ESActive, not recruitingNot Applicable
n ensayo internacional multicéntrico, aleatorizado, con grupos paralelos y doble enmascaramiento para evaluar distintas combinaciones de dosis de lercanidipino y enalapril en comparación con cada uno de los componentes administrados solos y con placebo en pacientes con hipertensión esencial.An international multicentre, randomized, parallel group, double-blind trial to evaluate different dose combinations of lercanidipine and enalapril in comparison with each component administered alone and with placebo in patients with essential hypertension.
Recordati S.p.A.,0 sites990 target enrollmentStarted: November 23, 2009Last updated:
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 990
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Male or female, aged 18 - 75 years.
- •- If females, the patient must be post-menopausal, surgically sterilized or, if child-bearing potential, non nursing and practicing an effective method of contraception throughout study duration (i.e. using oral or implanted contraceptive therapy or an intrauterine device). If naturally post-menopausal, the patient must not have had a menstrual period within 12 months prior to entry into the study.
- •- Non-hospitalized patients.
- •- Patients with essential hypertension (untreated or intolerant or not well controlled on current antihypertensive therapy), who are able to tolerate a drug-free period.
- •- Office BP: sitting diastolic blood pressure (SDBP) between 100 and 109 mmHg
- •(inclusive) and clinic sitting systolic blood pressure (SSBP) < 180 mmHg after a 2 week placebo run-in period.
- •- Home BP: diastolic blood pressure at home >= 85 mmHg in the last week of the run-in period.
- •- Normal ECG or with signs of LVH, first degree AV block, non specific ST-T wave
- •changes, or other changes not considered clinically significant.
- •- Satisfactory compliance to study medication (80-120%) during the run-in period.
- •- Available to return to all scheduled visits and to comply with protocol requirements.
- •- Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •- Severe hypertension (SSBP >= 180 mmHg or SDBP >= 110 mmHg)
- •- Patients with persistent differences in blood pressure between the two arms (>20 mmHg for SSBP or >10 mmHg for SDBP) on 3 immediately consecutive readings at Visit 1
- •- Known or suspected secondary hypertension (coarctation of the aorta, hyperaldosteronism, unilateral renal artery stenosis, pheochromocytoma, etc.)
- •- History of cerebrovascular complications (TIA, stroke, hypertensive encephalopathy)
- •History of cardiac complications (stable and unstable angina pectoris, myocardial
- •infarction, by-pass, PTCA, congestive heart failure NYHA Class II-IV)
- •- Hemodynamically significant valve disease, including aortic stenosis
- •- Clinically significant ventricular or supraventricular arrhythmia; heart rate >100
- •- Type 1 or Type 2 diabetes on drug treatment
- •- Severe renal or hepatic insufficiency
- •- Clinically important abnormal laboratory findings during the run-in period:
- •. Serum Creatinine >2 mg/dL
- •. AST (SGOT) and/or ALT (SGPT) and/or GGT > 3 times the upper limit of normal
- •. Fasting Plasma Glucose >= 126 mg/dL
- •. Hemoglobin <10 g/dL.
- •. Serum Potassium >5.5 mmol/L
- •. Serum Sodium < 132 mmol/L
- •- Any other clinically important renal, hematological, metabolic, neurological,
- •gastrointestinal, hepatic or pulmonary disorders or dysfunctions preventing study
- •participation (investigators assessment)
- •- History of malignancy within the previous 5 years (skin cancer other than melanoma is an exception)
- •- History of alcohol or drug abuse within the previous 2 years
- •- History of allergy, hypersensitivity, intolerance or contraindication to dihydropyridine
- •calcium antagonists or ACE inibitor
- •- Use of prohibited concomitant medications, including vasoactive products, strong
- •inhibitors of CYP3A4, ciclosporin and grapefruit juice (see Section 6.7 of study
- •- Participation in another clinical trial within 30 days prior to entry into the present study
- •- Any other condition, which, in the investigator's judgement, renders the patient unable to complete the study or increases the risk to the patient or which prevents optimal participation in achieving the objectives of the study.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Ensayo internacional, multicéntrico, aleatorizado, controlado, para evaluar el efecto del xenón en el delirio postoperatorio en pacientes ancianos que se someten a cirugía de fractura de cadera.Delirio postoperatorio en pacientes ancianos después de cirugía de fractura de cadera con anestesia general.MedDRA version: 12.1Level: LLTClassification code 10020100Term: Hip fractureEUCTR2009-017153-35-ESAIR LIQUIDE SANTE INTERNATIONA256
Active, not recruiting
Phase 1
Ensayo internacional, multicéntrico, aleatorizado, de grupos paralelos, doble ciego, controlado con placebo y con fármaco activo de eficacia y seguridad de fumarato de quetiapina de liberación sostenida (Seroquel LS™) en el tratamiento del trastorno de ansiedad generalizada (ensayo SILVER) - Ensayo SILVERTrastorno de ansiedad generalizada (TAG).EUCTR2005-005054-46-ESAstraZeneca AB805
Active, not recruiting
Not Applicable
n estudio multicentro, internacional, aleatorizado, doble ciego y de grupos paralelos que compara la administración de ACR16 45 mg una o dos veces al día frente al placebo, para el tratamiento sintomático de la Enfermedad de Huntington.(A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease) - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)Enfermedad de Huntington (Huntington's Disease)MedDRA version: 9.1Level: LLTClassification code 10020469Term: Huntington's choreaEUCTR2007-004988-22-ESeuroSearch Sweden AB420
Active, not recruiting
Not Applicable
Estudio internacional, multicéntrico, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo del efecto sobre la función cognitiva, la seguridad y la tolerabilidad de SAR110894D, administrado en dosis de 0,5 mg, 2 mg y 5 mg/día durante 24 semanas a pacientes con enfermedad de Alzheimer leve o moderada que reciben tratamiento estable con donepezilo__________________A multinational, multicenter, randomized, double-blind, parallel-group,placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapyDemencia tipo enfermedad de Alzheimer_______________Dementia Alzheimer's typeMedDRA version: 12.1Level: LLTClassification code 10012271Term: Dementia Alzheimer's typeEUCTR2010-022596-64-ESsanofi-aventis recherche & développement520
Active, not recruiting
Phase 1
Estudio internacional, multicéntrico, aleatorizado, doble ciego, doble enmascarado, y de grupos paralelos, para evaluar el tratamiento con SSR126517E (3,0 mg s.c. una vez por semana) frente a warfarina oral ajustada por INR durante 3 o 6 meses, de pacientes con embolismo pulmonar sintomático, con o sin trombosis venosa profunda sintomática. - CASSIOPEApacientes con embolismo pulmonar sintomático, con o sin trombosis venosa profunda sintomática confirmada.MedDRA version: 8.1Level: PTClassification code 10037377EUCTR2006-001786-42-ESsanofi-synthelabo recherche3,200